What's Going On With Chemomab Therapeutics Stock Today

Chemomab Therapeutics Ltd CMMB reported topline results from secondary Phase 2a liver fibrosis trial analyses assessing CM-101 in patients with non-alcoholic steatohepatitis (NASH). 

The results were included in a late-breaking poster presentation at the 2023 EASL Congress.

Overall, the data showed improvements across an additional set of inflammatory and fibrotic biomarkers consistent with the positive clinical results of Chemomab released in January. 

Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response than in those with a lower-risk disease or in placebo-treated patients.

The new analyses assessed additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk.

FAST scores were improved in a higher proportion of CM-101-treated patients than in placebo patients.

CM-101-treated patients with higher FAST scores demonstrated greater improvements in key fibro-inflammatory biomarkers, such as Pro-C3, than patients with lower FAST scores or placebo.

CM-101-treated patients with higher FAST scores showed improvements in several fibro-inflammatory biomarkers generally comparable to those achieved in several recent successful NASH clinical trials.

In these secondary analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation.

Price Action: CMMB shares are up 9.2% at $1.90 during the premarket session on the last check Wednesday.